Clin Exp Reprod Med.  2021 Sep;48(3):268-272. 10.5653/cerm.2020.04252.

Birth of a healthy infant after bone marrow-derived cell therapy

• Patel NH
• Jadeja YD
• Patel NH
• Patel MN
• Bhadarka HK
• Chudasama PN
• Thakkar HR

• KMID: 2520004
• DOI: http://doi.org/10.5653/cerm.2020.04252

Abstract

Bone marrow-derived cell (BMDC) therapy has numerous applications as potential biological cells for use in regenerative medicine. Here, we present an original case of endometrial atrophy associated with genital tuberculosis in a woman who achieved a live birth with BMDC. This 27-year-old woman came to our center with endometrial atrophy and primary infertility. She had a past history of genital tuberculosis and amenorrhea. Her husband’s semen quality was normal. The patient was counseled for hysteroscopy due to thin endometrium and advised in vitro fertilization (IVF) with donor eggs in lieu of poor ovarian reserve. Several attempts of IVF with hormone replacement therapy (HRT) were made, but the desired thickness of the endometrium was not achieved. Uterine artery injection of BMDC through interventional radiology was given, followed by HRT for three months, which resulted in improved endometrium. This was subsequently followed by IVF with donor egg. The treatment resulted in the conception and delivery of a 3.1-kg baby boy through lower segment caesarean section with no antenatal, intranatal or postnatal complications. Recently, there has been massive interest in stem cells as a novel treatment method for regenerative medicine, and more specifically for the regeneration of human endometrium disorders like Asherman syndrome and thin endometrium, which was the reason behind using this strategy for treatment.

Keyword

Bone marrow-derived cell therapy; Endometrial atrophy; Asherman’s syndrome; Stem cell therapy; Regenerative medicine